First US Field Test of GM Mosquitoes Begins in Florida

After years of push back, the first batch of Oxitec’s engineered mosquitoes, designed to reduce population numbers, have been released in the Keys.

Written byChristie Wilcox, PhD
| 2 min read
An Oxitec mosquito release box from the Florida Keys Friendly Mosquito Project

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

An Oxitec mosquito release box
OXITEC

Update (April 19, 2022): Oxitec presented results from their open-air Florida mosquito trial in a webinar on April 6. The trial went as expected, the firm reports, with all females that inherited the engineered gene dying before reaching adulthood, and the gene itself disappearing from the population after a few generations of mosquitoes. However, Nature notes that the trail was not designed for population suppression or quantifying public health impacts, so further trials are needed to determine if releases can have an impact on vector-borne diseases.

Update (March 10, 2022): The US Environmental Protection Agency extended Oxitec’s Experimental Use Permit for two years to allow the company to deploy additional genetically modified Aedes aegypti mosquitoes in Florida, as well as in four counties in California, where the mosquitoes have yet to be released. All together, the permit allows for up to 2.45 billion mosquitoes ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies